FDA Okays Appili Trial Expansion

The Food and Drug Administration in the U.S. has cleared Halifax-based Appili Therapeutics to expand its Phase 2 clinical trial of a drug that could help to prevent the spread of COVID-19 in long-term care facilities.

The company, which specializes in bringing anti-infectious drugs to market, said in May it would began Phase 2 trials of the drug Favipiravir in Canada, with the goal of proving it could help to prevent the spread of COVID-19.

Now the FDA has allowed Appili to expand the trial to encompass the U.S. as well as Canada. Appili intends to enroll as many as 760 participants in the